Introduction

Non-Hodgkin lymphomas (NHLs) are the fifth most frequently occurring cancer worldwide. Diffuse large B-cell lymphoma (DLBCL) is considered a highly heterogeneous type of NHL in its morphology, immunophenotypical, biological, and clinical aspects. Gene expression profile analysis has identified a germinal-center (GC) B-cell-like, an activated B-cell-like (ABC), and an intermediate type of DLBCL with different prognostic implications. Burkitt’s lymphoma (BL) is an aggressive B-cell NHL, characterized by a high degree of proliferation of the malignant cells. The main diagnostic challenge in BL is to distinguish it from DLBCL.

The gene expression patterns of BMPR2, EP300, TGFβ2, and TNFAIP3 in B-Lymphoma cells

Dong-Mei He, Hong Wu, Xiu-Li Wu, Li Ding, Ling Xu, Yang-Qiu Li

1Institute of Hematology, Medical College, 2Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou 510632, China

ABSTRACT

Objective: The results of a previous study showed that a clear dysregulation was evident in the global gene expression of the BCL11A-suppressed B-lymphoma cells. In this study, the bone morphogenetic protein receptor, type II (BMPR2), E1A binding protein p300 (EP300), transforming growth factor-β2 (TGFβ2), and tumor necrosis factor, and alpha-induced protein 3 (TNFAIP3) gene expression patterns in B-cell malignancies were studied.

Methods: The relative expression levels of BMPR2, EP300, TGFβ2, and TNFAIP3 mRNA in B-lymphoma cell lines, myeloid cell lines, as well as in cells from healthy volunteers, were determined by real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) with SYBR Green Dye. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as reference.

Results: The expression level of TGFβ2 mRNA in B-lymphoma cell lines was significantly higher than those in the cells from the healthy control (P<0.05). However, the expression level of TNFAIP3 mRNA in B-malignant cells was significantly lower than that of the healthy control (P<0.05). The expression levels of BMPR2 and EP300 mRNA showed no significant difference between B-malignant cell lines and the healthy group (P>0.05). In B-lymphoma cell lines, correlation analyses revealed that the expression of BMPR2 and TNFAIP3 (r=0.882, P=0.04) had significant positive relation. The expression levels of BMPR2, EP300, and TNFAIP3 mRNA in cell lines from myeloid leukemia were significantly lower than those in the cells from the healthy control (P<0.05). The expression levels of TGFβ2 mRNA showed no significant difference between myeloid leukemia cell lines and the healthy control or B-malignant cell lines (P>0.05). The expression levels of BMPR2, EP300, and TNFAIP3 mRNA in B-lymphoma cells were significantly higher than those of the myeloid leukemia cells (P<0.05).

Conclusion: Different expression patterns of BMPR2, EP300, TGFβ2, and TNFAIP3 genes in B-lymphoma cells exist.

KEYWORDS

Bone morphogenetic protein receptor, type II (BMPR2); E1A binding protein p300 (EP300); transforming growth factor-β2 (TGFβ2); tumor necrosis factor, and alpha-induced protein 3 (TNFAIP3); B-lymphoma cells; myeloid leukemia cells; quantitative reverse transcription polymerase chain reaction (qRT-PCR)
(BCL-11A) gene is associated with human malignant B cells, overexpression of which primarily occurs in B-cell lymphoma and B-cell leukemia. A previous study has shown that a broad range of genes may be altered in B-cell lymphoma, including bone morphogenetic protein receptor, type II (BMPR2), E1A binding protein p300 (EP300), transforming growth factor-β (TGFβ2), tumor necrosis factor, and alpha-induced protein 3 (TNFAIP3) gene (also known as A20), by analyzing the global gene expression profile in the GCB-derived DLBCL cell line SUDHL6 after BCL11A downregulation (in press).

Bone morphogenetic proteins (BMPs) are members of TGF-β superfamily of signaling molecules. Deregulation of BMPs signaling pathways has been reported in certain human cancers. BMPR2 has tumor-suppressive functions in mammary carcinoma and B-CLL. BMPR2 was strongly expressed in acute promyelocytic leukemia, as well as in AML-M4 and multiple myeloma. However, the role of BMPs in B-lymphoma remains unknown. The EP300 gene encodes the adenovirus E1A-associated cellular p300 transcriptional co-activator protein. It is important in the processes of cell proliferation and differentiation. TNFAIP3 is a putative tumor suppressor gene in B-cell lymphomagenesis and the frequency of TNFAIP3 gene inactivation was observed in different subtypes of NHL.

Although BMPR2, EP300, TGFβ2, and TNFAIP3 have been studied in lymphoma or leukemia, no report has compared the expression of the four genes among B-lymphoma cells, the healthy control, and myeloid leukemia. In this study, quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to analyze the expression levels of BMPR2, EP300, TGFβ2, and TNFAIP3 in B-lymphoma and myeloid leukemia cell lines.

Materials and methods

Cell lines

Human B-lymphoma cell lines (DG-75, EB1, OCI-LY-3, and SUDHL6) were kindly provided by Prof. Ailin Guo (Institute of Pathology, Cornell University). Human B-lymphoma cell lines (Daudi, Raji) and myeloid leukemia cell lines (HL-60, NB4, U937, and K562) were purchased from a cell bank in Shanghai, China. The cells were cultured at 37°C in an atmosphere containing 5% CO2 in RPMI-1640 medium supplemented with penicillin (100 U/mL), streptomycin (0.1 mg/mL), and 10% fetal calf serum.

Ten healthy volunteers served as control (seven males and three females, 22-62 years old; median age, 31 years). All procedures were conducted in accordance with the guidelines of Medical Ethics committees of the health bureau of Guangdong Province, PR China. Peripheral blood was collected by heparin anticoagulation. Peripheral blood mononuclear cells (PBMCs) were separated with the use of the Ficoll-Hypaque gradient centrifugation method.

RNA extraction and cDNA synthesis

RNA was extracted using the Trizol kit (Invitrogen, Carlsbad, CA, USA) and reversely transcribed into the first-strand cDNA with the use of random hexamer primers and the reverse transcriptase Superscript II Kit (Invitrogen, USA), according to the manufacturer’s instructions. RNA purity and concentration was measured with a spectrophotometer. The integrity of RNA was checked on a 1% agarose gel. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene by qRT-PCR was used to determine the quality of the synthesized cDNA.

Real-time quantitative PCR with SYBR green I

The 2-ΔΔCt × 100% method could be used to analyze the relative changes in gene expression from real-time quantitative PCR experiments. Before applying the method to detect gene expression level, the targeted genes and the GAPDH gene should be determined to have high amplification efficiency. Therefore, a validation experiment was conducted using template serial dilutions of the cell lines cDNA covering the five orders of magnitude, 0.0001, 0.001, 0.01, 0.1, and 1. Standard curves were generated by plotting the Ct values against the logarithm starting quantity of the series dilution of cDNA template. The slope and correlation coefficient (R2) were determined by linear regression analysis. Briefly, the primers were designed and synthesized (Invitrogen, USA). The following primer sequences used in PCR reactions were shown in Table 1. The total reaction volume is

| Primer | Sequence | Size (bp) |
|--------|----------|-----------|
| BMPR2-f | 5’ GGTCTAACTTATGATGATTGGGAA 3’ | 107 |
| BMPR2-r | 5’ CACGCCTATTATGTGACAGGTTGC 3’ |
| EP300-f | 5’ TCCGAGACATCTTGAGACGACAG 3’ | 107 |
| EP300-r | 5’ GGGTTGCTGGAACTGGTTATGG 3’ |
| TGFβ2-f | 5’ GTTCGATTTGACGTCTCAGCAAT 3’ | 107 |
| TGFβ2-r | 5’ CAATCCGTTTGTCACGCACT 3’ |
| TNFAIP3-f | 5’ CCACAAAGGCCCTCATGACAGCAG 3’ | 109 |
| TNFAIP3-r | 5’ GTCCGGTCTGCTCGTCTCAGAAAT 3’ | 114 |
| GAPDH-f | 5’ ACCCAGAAGACTGTGGATGG 3’ |
| GAPDH-r | 5’ TTCAGCTCAAGGATGACCTT 3’ |
The expression of BMPR2, EP300, TGFβ2, and TNFAIP3 genes in B-lymphoma cell lines

Ten malignancy hematology cell lines (six B-malignancy cells and four myeloid cells) were assayed for RNA expression levels. B-malignancy cells include Burkitt’s lymphoma cell lines (EB1, Daudi, DG75, and Raji) and GCB DLBCL-derived cell lines (OCI-LY-3 and SUDHL6). The mRNA expression level for each of the four genes was normalized to the reference gene (GAPDH). The ∆Ct was calculated for all four genes. According to the relative qRT-PCR formula: $2^{-\Delta Ct} \times 100\%$, the relative expression level of TGFβ2 mRNA in cell lines from B-cell malignancies was significantly higher than that in the cells from the healthy control ($P<0.05$). On the other hand, the expression level of TNFAIP3 mRNA in B-malignant cells was significantly lower than that of the healthy control ($P<0.05$). As shown in Figure 1, the median quantities of TGFβ2 and TNFAIP3 expression in these B-cell lines are 6.25% and 4.78%, respectively, whereas the relative median expression levels of the two genes in the healthy group are 0.12% and 164.74%. The relative expression levels of BMPR2 and EP300 mRNA indicated no significant difference between B-cell malignant cell lines and PBMNCs of the healthy group ($P>0.05$).

In B-lymphoma cell lines, correlation analyses revealed that the expression of BMPR2 and TNFAIP3 ($r=0.882$, $P=0.04$) had significant positive relation.

The expression levels of BMPR2, EP300, TGFβ2, and TNFAIP3 genes in myeloid leukemia cells

The relative expression levels of BMPR2, EP300, and TNFAIP3 mRNA in myeloid leukemia cells were found to be significantly different between the myeloid leukemia cell lines (C) and the healthy control ($P<0.05$).
mRNA in cell lines from myeloid leukemia were significantly lower than those in the cells from the healthy people (P<0.05). As shown in Figure 1, the median quantities of BMPR2, EP300, and TNFAIP3 expression in the myeloid leukemia cell lines are 0.10%, 0.56%, and 0.34%, respectively. Furthermore, the relative median expression levels of these genes in the healthy control are 2.04%, 19.05%, and 164.74%, respectively. The relative expression levels of TGFβ2 mRNA showed no significant difference between myeloid leukemia cell lines and the healthy control (P>0.05).

**BMPR2, EP300, TGFβ2, and TNFAIP3 gene expression in B-malignant and myeloid leukemia cell lines**

As shown in Figure 1, the relative expression levels of BMPR2, EP300, and TNFAIP3 mRNA in the cell lines from B-cell malignancy were significantly higher than those cell lines from myeloid leukemia (P<0.05), whereas the relative expression levels of TGFβ2 mRNA showed no significant difference between B-cell malignant cell lines and myeloid leukemia cell lines (P>0.05).

**Discussion**

In this study, BMPR2, EP300, TGFβ2, and TNFAIP3 mRNA expression were determined by qRT-PCR using SYBR Green I dye. Results showed that the high amplification efficiency of these genes was consistent with that of GAPDH, suggesting that the 2−ΔCt ×100% method can be used in quantifying the relative expression levels of the gene mRNA. This study revealed the expression of TGFβ2 and TNFAIP3 mRNA in B-malignant cells were significantly different from those of the healthy control. Meanwhile, the expression levels of BMPR2, EP300, and TNFAIP3 mRNA in myeloid leukemia cells were significantly lower than those of healthy people.

Deregulated or aberrant TGF-β signaling has been strongly implicated in the pathogenesis of human solid tumors, while less is known about the role of this pathway in lymphoma pathogenesis. TGF-β has either a tumor-suppressing or tumor-promoting function depending on cellular context. Moreover, TGF-β is overexpressed in chronic lymphocytic leukemia. TGF-β functions as an autocrine growth inhibitor in chronic lymphocytic leukemia B-cells. In the study of Ho et al., TGFβ2 was expressed in normal B-cell differentiation of the germinal center, especially from the follicular center cell stage to the postfollicular plasma cell stage. However, there was no expression of TGF-β in specimens from patients with neoplastic NHL. In this study, the expression level of TGFβ2 mRNA in PBMCs from the healthy control is almost lacking. The expression level of TGFβ2 mRNA in the cell lines from B-malignancies was significantly higher than those in the cells from the healthy control. Furthermore, TGF-β functions as either suppressing or promoting the effect on tumors need to be investigated. TNFAIP3 inactivation has been reported in various B-cell lymphomas. In GCB DLBCL, the expression of TNFAIP3 was lower than that in ABC DLBCL. Meanwhile, Paik et al. observed that TNFAIP3 deletion was in similar frequencies in GCB and non-GCB/ABC DLBCL using fluorescence in situ hybridization. These contradictory observations may reflect the diversified roles of TNFAIP3 in DLBCL. These results showed that the expression level of TNFAIP3 mRNA in B-malignant cells was significantly lower than that of the healthy control, suggesting possible deletion of TNFAIP3 gene in the B-lymphoma cells, which is in accordance with previous observations. More so, TNFAIP3 gene was expressed at lower levels in GCB DLBCL cell lines than in Burkitt’s lymphoma cell lines.

EP300 mutations were recently identified as a major pathogenetic mechanism shared by common forms of B-cell NHLs. By contrast, the findings in this study demonstrate that the expression levels of BMPR2 and EP300 mRNA had no significant difference between B-cell malignant cell lines and PBMCs of the healthy people.

Results indicate that the expression levels of BMPR2, EP300, and TNFAIP3 mRNA in myeloid leukemia cell lines were significantly lower than those of healthy people or B-malignant cell lines. BMPR2, EP300, and TNFAIP3 mRNA have been observed to be almost absent in myeloid leukemia cell lines. This observation indicates that the expression patterns of BMPR2, EP300, and TNFAIP3 in B-cell lymphoma may be significantly different from myeloid leukemia cell lines. Although the median quantity of TGFβ2 expression in B-lymphoma cell lines is obviously higher than that of the myeloid leukemia cell lines, no statistically significant difference is observed. This finding might denote a large variance of TGFβ2 expression level (three orders of magnitude) in the B-lymphoma cell lines. Additionally, in the different B-lymphocyte malignant cell lines, the expression levels of BMPR2, EP300, TGFβ2, and TNFAIP3 mRNA were quite different, which may be related to the heterogeneity of B-cell lymphoma.

Little is known about the expression correlation between BMPR2 and TNFAIP3 genes in B-cell lymphoma. This study showed that the expression of BMPR2 and TNFAIP3 had a significant positive relation in B-lymphoma cell lines. These results indicate that a positively correlated expression pattern
may be a feature in B-cell lymphoma. However, increasing the number of samples for validating the expression relation of the two genes is needed.

In conclusion, the expression patterns of BMPR2, EP300, TGFβ2, and TNFAIP3 genes were characterized in B-lymphoma cells. Meanwhile, the differential expression pattern needs to increase the sample numbers to be further studied in B-cell malignancies. In addition, further biological studies are needed to determine if TGFβ2 and TNFAIP3 are therapeutic targets for B-cell lymphoma.

Acknowledgements

The work was supported by the Guangdong Province Key Foundation of Science and Technology Program (Grant No. 2009B050700029), the Guangdong Province Science and Technology Program (Grant No. 2012B031800474), and a grant from the Overseas Chinese Affairs Office of the State Council Key Discipline Construction Fund (Grant No. 51205002).

Conflict of interest statement

No potential conflicts of interest are disclosed.

References

1. Deffenbacher KE, Iqbal J, Sanger W, Shen Y, Lachel C, Liu Z, et al. Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. Blood 2012;119:3757-3766.

2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.

3. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003;8:541-552.

4. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.

5. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.

6. Bellan C, Stefano L, Giulia de F, Rogena EA, Lorenzo L. Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach. Hematol Oncol 2010;28:53-56.

7. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med 2006;354:2431-2442.

8. Satterwhite E, Sonoki T, Willis TG, Harder L, Nowak R, Arriola EL, et al. The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. Blood 2001;98:3413-3420.

9. Liu H, Ippolito GC, Wall JK, Niu T, Probst L, Lee BS, et al. Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraseptiles of germinal center B cells. Mol Cancer 2006;5:18.

10. Yin B, Devel W, Valk PJ, Wallace MR, Loh ML, Shannon KM, et al. A retroviral mutagenesis screen reveals strong cooperation between BCL11A overexpression and loss of the NFκB tumor suppressor gene. Blood 2009;113:1075-1085.

11. Gao Y, He D, Chen S, Yan X, Hu X, Li Y. Expression of the B-cell lymphoma/leukemia 11A gene in malignant hematological cell lines through quantitative reverse transcription polymerase chain reaction. Clin Oncol Cancer Res 2011;8:242-246.

12. Dzietcznia J, Wrobel T, Jarzembic B, Mazur G, Butryn A, Porzycka R, et al. Expression of bone morphogenetic proteins (BMPs) receptors in patients with B-cell chronic lymphocytic leukemia (B-CLL). Int J Lab Hematol 2010;32:e217-221.

13. Owens P, Pickup MW, Novitskiy SV, Chytil A, Gorska AE, Aakre ME, et al. Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators. Proc Natl Acad Sci USA 2012;109:2814-2819.

14. Grcević D, Marušić A, Grahovac B, Jakšić B, Kusec R. Expression of bone morphogenetic proteins in acute promyelocytic leukemia before and after combined all-trans retinoic acid and cytotoxic treatment. Leuk Res 2003;27:731-738.

15. Garbati MR, Alço G, Gilmore TD. Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8. Cancer Lett 2010;291:237-245.

16. Iyer NG, Ozturk H, Caldas C. p300/CBP and cancer. Oncogene 2004;23:4225-4231.

17. Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y, et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009;114:2467-2475.

18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. Methods 2001;25:402-408.

19. Papakonstantinou G, Verbeke C, Hastkaja J, Bohrer M, Hehlmann R. bcl-2 expression in non-Hodgkin’s lymphomas is not associated with bcl-2 gene rearrangements. Br J Haematol 2001;113:383-390.

20. Lin HK, Bergmann S, Pandoli PP. Deregulated TGF-beta signaling in leukemogenesis. Oncogene 2005;24:s593-s570.

21. Ikushima H, Miyazono K. TGFbeta signalling: a complex web in
cancer progression. Nat Rev Cancer 2010;10:415-424.
22. Lotz M, Ranheim E, Kipps TJ. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med 1994;179:999-1004.
23. Ho CL, Sheu LF, Li CY. Immunohistochemical expression of angiogenic cytokines and their receptors in reactive benign lymph nodes and non-Hodgkin lymphoma. Ann Diagn Pathol 2003;7:1-8.
24. Paik JH, Go H, Nam SJ, Kim TM, Heo DS, Kim CW, et al. Clinicopathologic implication of A20/TNFAIP3 deletion in diffuse large B-cell lymphoma: an analysis according to immunohistochemical subgroups and rituximab treatment. Leuk Lymphoma 2013;54:1934-1941.
25. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011;471:189-195.

Cite this article as: He DM, Wu H, Wu XL, Ding L, Xu L, Li YQ. The gene expression patterns of BMPR2, EP300, TGFβ2, and TNFAIP3 in B-Lymphoma cells. Cancer Biol Med 2014;11:202-207. doi: 10.7497/jissn.2095-3941.2014.03.006